Summary:
«Health data platforms that participants trust could bring an end to today’s reductionist approach to drug development, revolutionizing our understanding of disease.»
«The past decade has seen an important and, for many patients, a life-changing rise in the number of innovative new drugs reaching the market to treat diseases such as multiple sclerosis, malaria, and subtypes of certain cancers (such as melanoma or leukemia). In the United States, the Food and Drug Administration approved an average of 41 new molecular entities (including biologic license applications) each year from 2011 to 2020—almost double the number in the previous decade.1 Despite the immense costs of such achievements,2 biopharmaceutical researchers have not yet uncovered a universal, systematic approach to generate many more breakthroughs or predict which interventions will work for which patients.»
Article written by Matthias Evers, Lucy Pérez, Lucas Robke, and Katarzyna Smietana. Photo by Braňo on Unsplash
15|04|2022
Source:
McKinsey